VESALIUS-CV (TIMI 66)

VESALIUS-CV will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.

VESALIUS-CV_Trial Design_04Oct2022_updated

VESALIUS-CV on ClinicalTrials.gov

CONTACT US About VESALIUS

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close